Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 433-444

  Milczarek, Magdalena ^a   Rosinska, Sara ^a   Psurski, Mateusz ^a,b   Maciejewska, Magdalena ^a   Kutner, Andrzej ^c   Wietrzyk, Joanna ^a,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^d JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Anticancer activity; Colonic cancer; Combined treatment; Irinotecan; Oxaliplatin; Vitamin D analogs

Indexed keywords

IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PRI 2191; PRI 2205; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIHYDROXYCHOLECALCIFEROLS; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS; SIGNAL TRANSDUCTION; VITAMIN D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875528506     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Lamprecht SA and Lipkin M: Chemoprevention of colon cancer by calcium, vitamin D and folate: Molecular mechanisms. Nat Rev Cancer 3: 601-614, 2003.
2. McCarthy TC, Li X and Sinal CJ: Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 280: 23232-23242, 2005.
3. Terry P, Baron JA, Bergkvist L, Holmberg L and Wolk A: Dietary calcium and vitamin D intake and risk of colorectal cancer: A prospective cohort study in women. Nutr Cancer 43: 39-46, 2002.
4. Sintov AC, Berkovich L and Ben-Shabat S: Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D(3) analogs, in vitro and in vivo studies. Invest New Drugs, Jun 2, 2012.
5. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR and Heber D: Vitamin D, calcium supplementation, and colorectal adenomas: Results of a randomized trial. J Natl Cancer Inst 95: 1765-1771, 2003.
6. Hartman TJ, Albert PS, Snyder K, Slattery ML, Caan B, Paskett E, Iber F, Kikendall JW, Marshall J, Shike M, Weissfeld J, Brewer B, Schatzkin A and Lanza E: The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 135: 252-259, 2005.
7. Baniahmad A and Tsai MJ: Mechanisms of transcriptional activation by steroid hormone receptors. J Cell Biochem 51: 151-156, 1993.
8. Saramaki A, Banwell CM, Campbell MJ and Carlberg C: Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 34: 543-554, 2006.
9. Nagpal S, Na S and Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26: 662-687, 2005.
10. Matusiak D, Murillo G, Carroll RE, Mehta RG and Benya RV: Expression of vitamin D receptor and 25-hydroxyvitamin D3-1α-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 14: 2370-2376, 2005.
11. Zhao X and Feldman D: Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology 132: 1808-1814, 1993.
12. Gaschott T, Werz O, Steinmeyer A, Steinhilber D and Stein J: Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 288: 690-696, 2001.
13. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M and Munoz A: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154: 369-387, 2001.
14. Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG and Munoz A: Effects of 1α,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 26: 2669-2681, 2006.
15. Pena C, Garcia JM, Silva J, Garcia V, Rodriguez R, Alonso I, Millan I, Salas C, de Herreros AG, Munoz A and Bonilla F: ECadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: Clinicopathological correlations. Hum Mol Genet 14: 3361-3370, 2005.
16. Larriba MJ and Munoz A: SNAIL vs. vitamin D receptor expression in colon cancer: Therapeutic implications. Br J Cancer 92: 985-989, 2005.
17. Palmer HG, Larriba MJ, Garcia JM, Ordonez-Moran P, Pena C, Peiro S, Puig I, Rodriguez R, de la FR, Bernad A, Pollan M, Bonilla F, Gamallo C, de Herreros AG and Munoz A: The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 10: 917-919, 2004.
18. Mokady E, Schwartz B, Shany S and Lamprecht SA: A protective role of dietary vitamin D3 in rat colon carcinogenesis. Nutr Cancer 38: 65-73, 2000.
19. Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM and Holick MF: Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 135: 2350-2354, 2005.
20. 3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 51: 2848-2853, 1991.
21. 3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59: 862-867, 1999.
22. Siwinska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, Szelejewski W and Radzikowski C: Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res 21: 1925-1929, 2001.
23. Pelczynska M, Switalska M, Maciejewska M, Jaroszewicz I, Kutner A and Opolski A: Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer Res 26: 2701-2705, 2006.
24. Opolski A, Wietrzyk J, Siwinska A, Marcinkowska E, Chrobak A, Radzikowski C and Kutner A: Biological activity in vitro of side-chain modified analogues of calcitriol. Curr Pharm Des 6: 755-765, 2000.
25. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E and Ikeda K: A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837, 1991.
26. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E and Ikeda K: Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 53: 2534-2537, 1993.
27. Wietrzyk J, Nevozhay D, Filip B, Milczarek M and Kutner A: The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res 27: 3387-3398, 2007.
28. Wietrzyk J, Nevozhay D, Milczarek M, Filip B and Kutner A: Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol 62: 787-797, 2008.
29. Wietrzyk J, Pelczynska M, Madej J, Dzimira S, Kusnierczyk H, Kutner A, Szelejewski W and Opolski A: Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids 69: 629-635, 2004.
30. Wietrzyk J, Chodynski M, Fitak H, Wojdat E, Kutner A and Opolski A: Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs 18: 447-457, 2007.
31. Pajtasz-Piasecka E, Szyda A, Rossowska J, Krawczenko A, Indrova M, Grabarczyk P, Wysocki P, Mackiewicz A and Dus D: Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha) 50: 7-14, 2004.
32. Education and Training in the Care and Use of Laboratory Animals: A Guide for Developing Institutional Programs. The National Academies Press, 1991.
33. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM and Ackland SP: Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227-253, 2000.
34. Danilenko M and Studzinski GP: Enhancement by other compounds of the anticancer activity of vitamin D3 and its analogs. Exp Cell Res 298: 339-358, 2004.
35. Mutlu H, Colak T, Ozdogan M, Altuner TY and Akca Z: The effect of seasonal differences on prognostic factors in Turkish patients with breast cancer. Eur J Cancer Prev 20: 475-477, 2011.
36. Turna A, Pekcolaklar A, Metin M, Yaylim I and Gurses A: The effect of season of operation on the survival of patients with resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg 14: 151-155, 2012.
37. Grant WB and Garland CF: The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res 26: 2687-2699, 2006.
38. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD and Johnson CS: Antitumor activity of calcitriol: Pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89-90: 519-526, 2004.
39. 3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 1: 821-829, 2002.
40. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL and Johnson CS: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759-3764, 1997.
41. Cvitkovic E and Bekradda M: Oxaliplatin: A new therapeutic option in colorectal cancer. Semin Oncol 26: 647-662, 1999.
42. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M and Falcone A: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249: 420-425, 2009.
43. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G and Gansl RC: Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer 11: 93-100, 2012.
44. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M and Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85: 2293-2297, 2001.
45. Diaz GD, Paraskeva C, Thomas MG, Binderup L and Hague A: Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 60: 2304-2312, 2000.
46. Palmer HG, Anjos-Afonso F, Carmeliet G, Takeda H and Watt FM: The vitamin D receptor is a Wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS ONE 3: e1483, 2008.
47. Saramaki A, Banwell CM, Campbell MJ and Carlberg C: Regulation of the human p21WAF1/CIP1 gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 34: 543-554, 2006.
48. Chen A, Davis BH, Bissonnette M, Scaglione-Sewell B and Brasitus TA: 1,25-Dihydroxyvitamin D3 stimulates activator protein-1-dependent Caco-2 cell differentiation. J Biol Chem 274: 35505-35513, 1999.
49. Wang X, Li M, Wang J, Yeung CM, Zhang H, Kung HF, Jiang B and Lin MC: The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol 71: 1540-1550, 2006.
50. Cui M, Zhao Y, Hance KW, Shao A, Wood RJ and Fleet JC: Effects of MAPK signaling on 1,25-dihydroxyvitamin Dmediated CYP24 gene expression in the enterocyte-like cell line, Caco-2. J Cell Physiol 219: 132-142, 2009.